These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18991801)

  • 21. Treatment of visceral leishmaniasis with amphotericin B colloidal dispersion.
    Berman J; Dietze R
    Chemotherapy; 1999 Jun; 45 Suppl 1():54-66. PubMed ID: 10394022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral miltefosine treatment in children with visceral leishmaniasis: a brief review.
    Palumbo E
    Braz J Infect Dis; 2008 Feb; 12(1):2-4. PubMed ID: 18553005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis.
    Murray HW
    Expert Rev Anti Infect Ther; 2004 Apr; 2(2):279-92. PubMed ID: 15482193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comprehensive review of patented antileishmanial agents.
    Rama M; Kumar NV; Balaji S
    Pharm Pat Anal; 2015 Jan; 4(1):37-56. PubMed ID: 25565159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of visceral leishmaniasis.
    Sundar S
    Med Microbiol Immunol; 2001 Nov; 190(1-2):89-92. PubMed ID: 11770119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug combinations for visceral leishmaniasis.
    Olliaro PL
    Curr Opin Infect Dis; 2010 Dec; 23(6):595-602. PubMed ID: 20871400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug unresponsiveness & combination therapy for kala-azar.
    Jha TK
    Indian J Med Res; 2006 Mar; 123(3):389-98. PubMed ID: 16778318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
    Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
    Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical aspects of visceral leishmaniasis in HIV infection.
    Jarvis JN; Lockwood DN
    Curr Opin Infect Dis; 2013 Feb; 26(1):1-9. PubMed ID: 23221770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The treatment of visceral leishmaniasis: safety and efficacy.
    Jha RK; Sah AK; Shah DK; Sah P
    JNMA J Nepal Med Assoc; 2013; 52(192):645-51. PubMed ID: 25327244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India.
    Singh N; Chatterjee M; Sundar S
    Parasit Vectors; 2014 Dec; 7():596. PubMed ID: 25515494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of resistant visceral leishmaniasis with interferon gamma in combination with liposomal amphotericin B and allopurinol.
    Khodabandeh M; Rostami A; Borhani K; Gamble HR; Mohammadi M
    Parasitol Int; 2019 Oct; 72():101934. PubMed ID: 31129197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004.
    Olliaro PL; Guerin PJ; Gerstl S; Haaskjold AA; Rottingen JA; Sundar S
    Lancet Infect Dis; 2005 Dec; 5(12):763-74. PubMed ID: 16310148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of visceral leishmaniasis in children].
    Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM
    Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Visceral leishmaniasis: new drugs].
    Minodier P; Robert S; Retornaz K; Garnier JM
    Arch Pediatr; 2003 Dec; 10 Suppl 5():550s-556s. PubMed ID: 15022780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leishmaniasis: current treatment and prospects for new drugs and vaccines.
    Kedzierski L; Sakthianandeswaren A; Curtis JM; Andrews PC; Junk PC; Kedzierska K
    Curr Med Chem; 2009; 16(5):599-614. PubMed ID: 19199925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in the treatment of leishmaniasis.
    Sundar S; Rai M
    Curr Opin Infect Dis; 2002 Dec; 15(6):593-8. PubMed ID: 12821836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current approaches to visceral leishmaniasis treatment in solid organ transplant recipients.
    Clemente WT; Mourão PHO; Aguado JM
    Expert Rev Anti Infect Ther; 2018 May; 16(5):391-397. PubMed ID: 29737887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.